< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 63
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
21 - 30 of 998
- Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study(2023)
Authors: Zhigang Wang, Bram Verstockt, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Erwin Dreesen
Pages: 3188 - 3190 - Phage therapy for hidradenitis suppurativa: a unique challenge and possible opportunity for personalized treatment of a complex, inflammatory disease.(2023)
Authors: Lene Bens, Sabrina Green, Daan Jansen, Tom Hillary, Jelle Matthijnssens, João Guedelha Sabino, Séverine Vermeire, An Van Laethem, Jeroen Wagemans, Rob Lavigne
Pages: 1221 - 1229 - Community Types of the Human Gut Virome are Associated with Endoscopic Outcome in Ulcerative Colitis(2023)
Authors: Daan Jansen, Gwen Falony, Jeroen Raes, Séverine Vermeire, Jelle Matthijnssens
Pages: 1504 - 1513 - Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.(2023)
Authors: Debby Thomas, Séverine Vermeire
- Managing metastatic Crohn's disease: a single center experience, review of the current evidence, and treatment algorithm(2023)
Authors: Judith Wellens, Gert De Hertogh, An Van Laethem, João Guedelha Sabino, Tom Hillary, Séverine Vermeire
Pages: 1122 - 1130 - Impact of Prior Biologic/Janus Kinase Inhibitor Therapy on the Efficacy of Etrasimod: Subgroup Analysis From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials(2023)
Authors: Séverine Vermeire
Pages: S813 - S814 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 9.2 Years of Safety Data From the Global Clinical Program(2023)
Authors: Séverine Vermeire
Pages: S910 - S910 - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment: Interim Results From the LUCENT-3 Open-Label Extension Study(2023)
Authors: Séverine Vermeire
Pages: S627 - S627 - Association of Nonswitched Memory B-Cell (MBC) Levels With Ozanimod (OZA) Efficacy in Patients (Pts) With Moderately to Severely Active Crohn's Disease (CD): Results From the Phase 2 STEPSTONE Study(2023)
Authors: Séverine Vermeire
Pages: S867 - S868 - Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program(2023)
Authors: Séverine Vermeire
Pages: S816 - S817
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)